1. Dieterich DT et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clinical Infectious Diseases 38:S80–S89, 2004.
2. Stern JO et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. JAIDS 34(1):S21-33, 2003.
3. CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after hiv exposures - worldwide, 1997–2000. MMWR; 51 & 52:1153–1156, 2001.
4. Bango F - Is it safe to substitute nevirapine for efavirenz in women with high CD4 counts on ART? The experience from Khayelitsha. 4th South African AIDS Conference, Durban, 2009.
5. Sanne I et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. JID, 191:825–9, 2005.
6. Hitti JH et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acq Immune Defic Syndr36(3): 772-6, 2004.
7. Gonzalez-Garcia A et al. Nevirapine toxicity in the obstetrical population when used in combination with other antiretrovirals. The XV International AIDS Conference, Bangkok, abstract no. WePeB5918, 2004.
8. Phanuphak N et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Medicine 8(6): 357-366, 2007.
9. Marazzi MC et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Medicine. Volume 7, Issue 5, Pages 338-344, 2006.
10. Jamisse L et al. Antiretroviral-associated toxicity among HIV-1–seropositive pregnant women in Mozambique receiving nevirapine-based regimens. JAIDS 44(4): 371-376, 2007.
11. Joao EC et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol; 194:199–202, 2006.
12. Kondo W et al. Nevirapine-induced side effects in pregnant women – experience of a Brazilian university hospital. Braz J Infect Dis.11(6), 2007.
13. Bottaro E et al. Nevirapine-associated toxicity in a HIV positive cohort in Buenos Aires, Argentina. XVII International AIDS Conference, Mexico City, abstractTHPE0201, 2008.
14. Lyons, F et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Medicine 7(4) 255-260, 2006.
15. Timmermans S et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS.;19:795-799, 2005
16. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/ml. AIDS 20(17): 2233-2235, 2006.
17. Nunez M, Martin-Carbonero L, Soriano V. Impact of hepatitis C virus (HCV) on morbidity and mortality rates among HIV-infected patients. Clin Infect Dis; 37:460–461, 2003.
18. Martin A et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1_0101 and abrogated by low CD4+ T cell counts. AIDS; 19:97–99, 2005.
19. Littera R et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20: 1621-1626, 2006.
20. Gatnaga H et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS; 21:264–265, 2007.
21. Tian W et al. MICA, HLA-B haplotypic variation in five population groups of sub-Saharan African ancestry. Genes and Immunity 4, 500–505, 2003.
22. Sanchez-Mazas A. African diversity from the HLA point of view: influence of genetic drift, geography, linguistics, and natural selection. Hum Immunol. 62(9):937-48, 2001.
23. Liechty C et al. Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 2005; 19:993–994, 2005
20. Gatnaga H et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS; 21:264–265, 2007.
24. Harris M. Efficacy and durability of nevirapine in antiretroviral-experienced patients. J AIDS 34 (Suppl): 53-58, 2003.
25. Mocroft A, Staszewski S, Weber R, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced patients with high and low CD4 counts. Antivir Ther 12:325–33, 2007.
26. De Roo A. Incidence of rash and severe hepatotoxicity in patients switching from a protease inhibitor (PI) or efavirenz (EFV) to nevirapine (NVP) at relatively high CD4 count levels. XVI International AIDS Conference, Toronto, abstract CDB0697, 2006.
27. Wolf E, Koegl C, Theobald T. Nevirapine-associated hepatotoxicity: No increased risk for females or high CD4 count in a single centre HIV cohort. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, abstract H-1063, 2006.
28. Kumarasamy N et al. Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr 45: 598–600, 2007.
29. De Lazzari E et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med. 9(4):221-226, 2008.
30. Ena J et al. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. HIV Med. 9(9):747-756, 2008.
31. Wit FWMN et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive Patients: the ATHENA cohort Study. Clinical Infectious Diseases 46:933–940, 2008.
32. Dufty N et al. Switching from efavirenz (EFV) to nevirapine (NVP): a novel pharmacological strategy. HIV Medicine 10 suppl 1: 7 (abstract 21), 2009.
33.Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989 - 31 January 2008. Wilmington, NC: Registry Coordinating Center; Available at: http://www.APRegistry.com
34. Bussmann H et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. Journal of Acquired Immune Deficiency Syndromes 45(3):269-273, 2007.
35. Roussoux T. Quantifying antiretroviral risk in pregnancy. SAMJ 97(11): 1015-1016, 2007.
36. Bera E et al. Birth defects and perinatal outcomes from 748 pregnant women who took efavirenz as part of lifelong antiretroviral therapy. A prospective study at a tertiary hospital in South Africa. 4th South African AIDS Conference, Durban, abstract 395, 2009.
37. Chersich MF et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Research and Therapy 3 (11), 2006.